Literature DB >> 2825524

Treatment of nonmetastatic gestational trophoblastic disease with oral methotrexate.

J F Barter1, S J Soong, K D Hatch, J W Orr, E C Partridge, J M Austin, H M Shingleton.   

Abstract

Fifteen patients with nonmetastatic gestational trophoblastic disease were treated solely with methotrexate given orally rather than intramuscularly. Remission, defined as a beta-human chorionic gonadotropin titer of less than 5 mIU/ml for 3 consecutive weeks, was attained in 13 (87%) of the 15 patients. Level of toxicity was acceptable. Patient comfort, convenience, and less time off work and in the physician's office are significant advantages to this efficacious, well-tolerated method of therapy.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2825524     DOI: 10.1016/s0002-9378(87)80285-5

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  4 in total

1.  Gestational trophoblastic disease following complete hydatidiform mole in Mulago Hospital, Kampala, Uganda.

Authors:  Dan K Kaye
Journal:  Afr Health Sci       Date:  2002-08       Impact factor: 0.927

2.  Gestational Trophoblastic Neoplasia Treatment at the Butaro Cancer Center of Excellence in Rwanda.

Authors:  Ignace Nzayisenga; Roanne Segal; Natalie Pritchett; Mary J Xu; Paul H Park; Edgie V Mpanumusingo; Denis G Umuhizi; Donald P Goldstein; Ross S Berkowitz; Vedaste Hategekimana; Clemence Muhayimana; Fidel Rubagumya; Temidayo Fadelu; Neo Tapela; Tharcisse Mpunga; Rahel G Ghebre
Journal:  J Glob Oncol       Date:  2016-04-13

3.  Anti-cancer therapy and clinical trial considerations for gynecologic oncology patients during the COVID-19 pandemic crisis.

Authors:  Bhavana Pothuri; Angeles Alvarez Secord; Deborah K Armstrong; John Chan; Amanda N Fader; Warner Huh; Joshua Kesterson; Joyce F Liu; Kathleen Moore; Shannon N Westin; R Wendel Naumann
Journal:  Gynecol Oncol       Date:  2020-04-23       Impact factor: 5.482

4.  Differences in Administration of Methotrexate and Impact on Outcome in Low-Risk Gestational Trophoblastic Neoplasia.

Authors:  Emelie Wallin; Isa Niemann; Louise Faaborg; Lars Fokdal; Ulrika Joneborg
Journal:  Cancers (Basel)       Date:  2022-02-08       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.